Syncell Launches High-Precision Proteomics Service to Map Unseen Proteins

LIVERMORE, Calif. & TAIPEI, Taiwan – May 28, 2026 – Life sciences company Syncell today commercially launched a service that promises to give researchers a new, ultra-precise lens into the fundamental machinery of disease. The Syncell Discovery Services program opens global access to the company's flagship Microscoop® Mint platform, a technology designed to identify novel proteins at the subcellular level where disease often begins, a feat that has largely eluded conventional methods.

For years, scientists have faced a critical bottleneck in understanding disease: they could only find what they were already looking for. Most spatial proteomics methods, which map proteins within their native tissue context, rely on predefined antibody panels. This approach is effective for studying known biomarkers but creates a significant blind spot for discovering novel proteins involved in disease pathways. Syncell aims to eliminate that blind spot.

The new service provides biopharma companies, research organizations, and academic labs with an end-to-end workflow, from sample submission to data-rich discovery. It leverages an unbiased approach that can characterize the entire proteome of a specific, nanoscopic region within a cell, accelerating the hunt for new drug targets and biomarkers across oncology, neuroscience, and immunology.

A New Lens on Cellular Biology

At the heart of the service is the Microscoop® Mint platform, which operates on a principle of microscopy-guided photochemistry. Instead of using antibodies, the system uses a high-precision light source to illuminate a specific subcellular area of interest—as small as 350 nanometers—and tags all proteins within that tiny region. These tagged proteins are then extracted and analyzed using high-sensitivity mass spectrometry, providing a complete and unbiased census of the proteome at that exact location.

This capability addresses a long-standing challenge, as articulated by early users of the technology. "Our lab has extensive experience with spatial proteomics but the general dependence of these methods on antibody panels was a major limitation," said William Hwang, M.D, Ph.D., at Massachusetts General Hospital and Assistant Professor at Harvard Medical School. Dr. Hwang's team was investigating cellular interactions in cancer but was stymied because the key proteins were unknown, making it impossible to design an effective antibody panel.

"We were stuck until we learned about Microscoop," he continued. "This unbiased spatial optoproteomics approach allowed us, for the first time, to identify candidates in the protein adhesion complex at the whole proteome level, which we are now functionally validating as potential drug targets for cancer." This experience highlights the platform's potential to break through research roadblocks and uncover entirely new avenues for therapeutic intervention.

A Strategic Play in a Booming Market

Syncell's launch enters a dynamic and rapidly expanding spatial OMICS market, which is projected to surpass $3.3 billion by 2034. While established players like 10x Genomics, Akoya Biosciences, and NanoString Technologies have made significant strides, particularly in spatial transcriptomics and antibody-based proteomics, Syncell is carving out a distinct niche with its focus on unbiased, nanoscopic protein discovery.

By offering its technology as a service, Syncell lowers the barrier to entry for research groups that may not have the capital to purchase the instrument outright. The company has structured its offerings into three tiers: 'Signature discovery' for exploratory projects, 'Comparative profiling' for differential analysis across disease states, and 'Program partnership' for deep, multi-study collaborations with pharmaceutical groups. This flexible model is designed to attract a wide range of customers, from academic labs testing novel hypotheses to large biopharma companies conducting extensive mechanism-of-action studies.

Evidence of strong market demand is already apparent. "During the pilot phase of Syncell Discovery Services, demand quickly outpaced capacity, with customers identifying proteins not previously known to be at their site of interest," said Nikhil Rao, Ph.D., Chief Commercial Officer at Syncell. This oversubscription suggests that the research community is eager for tools that can provide deeper, more fundamental biological insights beyond the scope of existing technologies.

Powering Discovery Through Partnership

The technical power of the Syncell Discovery Services is significantly amplified by a strategic integration with Thermo Fisher Scientific's state-of-the-art mass spectrometry technology. The end-to-end workflow combines Syncell's proprietary Microscoop platform and Synlight reagents with Thermo Fisher's ultra-sensitive Orbitrap™ Astral™ mass spectrometer.

This collaboration creates a formidable tool for proteomic analysis. While the Microscoop platform provides unparalleled precision in isolating proteins from a specific subcellular location, the Orbitrap Astral offers the unmatched sensitivity and speed required to identify and quantify those proteins, even those present in very low numbers. The combination enables researchers to achieve deep proteome coverage from minuscule starting material, revealing a level of spatial and chemical detail that was previously inaccessible.

This integrated workflow not only enhances data quality but also boosts throughput, allowing for the analysis of more samples in less time. For researchers, this means faster and more robust results, accelerating the entire discovery-to-validation pipeline. The partnership effectively combines a best-in-class spatial purification front-end with a best-in-class analytical back-end, creating a powerful solution that reinforces the credibility and scalability of Syncell's approach.

From Lab Bench to Future Therapies

The ultimate promise of this technology lies in its potential to transform patient care. By enabling the discovery of novel protein targets and biomarkers directly at the site where disease unfolds, Syncell's platform could fundamentally change how new drugs are developed.

"Today’s technology is unable to discover novel biomarkers at the site-specific, subcellular locations where disease actually unfolds — and that gap matters,” stated Rao. He noted that many fields are still reliant on a handful of known biomarkers, leaving vast therapeutic potential untapped. "The next generation of blockbuster targets [are] hidden in plain sight."

In oncology, researchers can now explore the intricate protein interactions within the tumor microenvironment with unprecedented clarity. In neuroscience, they can investigate the specific proteomic changes occurring at synapses in neurodegenerative diseases. This deeper understanding of disease biology is the first and most critical step toward developing more effective, highly targeted therapies.

As Syncell expands its service provider network globally, more researchers will gain the ability to look inside the cell's most complex and secretive compartments. This newfound vision into the nanoscopic world of proteins may very well illuminate the path to the next major breakthroughs in medicine.